ClinicalTrials.gov Studies Scraper

ClinicalTrials.gov scraper returns public study records from the official registry API. Clinical trials API rows include study status, conditions, interventions, sponsors, dates, and registry links.

Combine condition, intervention, location, overall status, phase, study start date and last-update-posted date filters. Alternatively, look up a list of NCT IDs. Results include sponsors, enrollment, eligibility, interventions, study locations and outcome definitions, along with the original study URL and retrieval timestamp.

What it returns

Each successful row has rowType: "study". Missing top-level scalar values remain null; absent top-level lists are empty. Optional fields inside list entries can be null. Dates retain the precision published by the source, including YYYY-MM values. Enumerations such as PHASE3 and COMPLETED keep the official API values.

Field	Type	Example value
rowType	string	"study"
nctId	string	"NCT06109311"
briefTitle	string	"A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor"
officialTitle	string	"A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor"
acronym	string	"ACHIEVE-5"
overallStatus	string	"COMPLETED"
lastKnownStatus	null	null
studyType	string	"INTERVENTIONAL"
phases	array	["PHASE3"]
conditions	array	["Type 2 Diabetes"]
interventions	array	[{"type": "DRUG", "name": "Orforglipron", "description": "Administered orally.", "otherNames": ["LY3502970"]}, {"type": "DRUG", "name": "Placebo", "description": "Administered orally.", "otherNames": null}]
leadSponsor	string	"Eli Lilly and Company"
leadSponsorClass	string	"INDUSTRY"
collaborators	array	[]
enrollmentCount	integer	546
enrollmentType	string	"ACTUAL"
hasResults	boolean	true
briefSummary	string	"The main purpose of this study is to determine the safety and efficacy of orforglipron. Participants will have Type 2 Diabetes (T2D) and have inadequate glycemic control with insulin glargine with or without metformin and/or SGLT-2 (sodium-glucose cotransporter-2) inhibitor. The study will last about 46 weeks and may include up to 20 visits."
eligibilityCriteria	string	"Inclusion Criteria:\n\n* Have Type 2 Diabetes (T2D)\n* Have HbA1c ≥7.0% \\[53 mmol/mol\\] to ≤10.5% \\[91 mmol/mol\\]\n* Have been treated with stable doses of the same formulation of the following for ≥90 days prior to screening visit 1 and have maintained the same doses through randomization:\n\n * insulin glargine U-100 (100 U/mL) ≥0.25 U/kg/QD (units per kilogram per day) or ≥20 U/QD alone, or\n * insulin glargine U-100 (100 U/mL) ≥0.25 U/kg/QD or ≥20 U/QD in combination with\n * metformin, or\n * SGLT-2 inhibitor, or\n * both metformin and SGLT-2 inhibitor.\n* Are of stable body weight (±5%) for at least 90 days prior to screening visit 1 and agree to not initiate an intensive diet or exercise program during the study with the intent of reducing body weight, other than the lifestyle and/or dietary measures for diabetes treatment.\n* Have a Body Mass Index (BMI) ≥23.0 kg/m\\^2 at baseline.\n\nExclusion Criteria:\n\n* Have New York Heart Association functional classification III-IV congestive heart failure.\n* Have had any of the following cardiovascular conditions within 60 days prior to baseline.\n\n * acute myocardial infarction\n * cerebrovascular accident (stroke), or\n * hospitalization for congestive heart failure.\n* Have acute or chronic hepatitis, including a history of autoimmune hepatitis, signs or symptoms of any other liver disease other than nonalcoholic fatty liver disease\n* Have had chronic or acute pancreatitis any time."
sex	string	"ALL"
minimumAge	string	"18 Years"
maximumAge	string	"18 Years"
healthyVolunteers	boolean	false
locations	array	[{"facility": "MD First Research - Chandler", "status": null, "city": "Chandler", "state": "Arizona", "zip": "85286", "country": "United States", "geoPoint": {"lat": 33.30616, "lon": -111.84125}}, {"facility": "Phoenix Clinical LLC", "status": null, "city": "Phoenix", "state": "Arizona", "zip": "85014", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "SanRo Clinical Research Group", "status": null, "city": "Bryant", "state": "Arkansas", "zip": "72022", "country": "United States", "geoPoint": {"lat": 34.59593, "lon": -92.48905}}, {"facility": "Velocity Clinical Research, Gardena", "status": null, "city": "Gardena", "state": "California", "zip": "90247", "country": "United States", "geoPoint": {"lat": 33.88835, "lon": -118.30896}}, {"facility": "Loma Linda University Health System", "status": null, "city": "Loma Linda", "state": "California", "zip": "92350", "country": "United States", "geoPoint": {"lat": 34.04835, "lon": -117.26115}}, {"facility": "Western University of Health Sciences", "status": null, "city": "Pomona", "state": "California", "zip": "91766", "country": "United States", "geoPoint": {"lat": 34.05529, "lon": -117.75228}}, {"facility": "Med Partners, Inc. dba Premiere Medical Center of Burbank, Inc.", "status": null, "city": "Toluca Lake", "state": "California", "zip": "91602", "country": "United States", "geoPoint": {"lat": 34.15206, "lon": -118.35719}}, {"facility": "CMR of Greater New Haven, LLC", "status": null, "city": "Hamden", "state": "Connecticut", "zip": "06517", "country": "United States", "geoPoint": {"lat": 41.39593, "lon": -72.89677}}, {"facility": "Care Access - Brandon", "status": null, "city": "Brandon", "state": "Florida", "zip": "33510", "country": "United States", "geoPoint": {"lat": 27.9378, "lon": -82.28592}}, {"facility": "Encore Medical Research", "status": null, "city": "Hollywood", "state": "Florida", "zip": "33024", "country": "United States", "geoPoint": {"lat": 26.0112, "lon": -80.14949}}, {"facility": "Encore Medical Research - Weston", "status": null, "city": "Weston", "state": "Florida", "zip": "33331", "country": "United States", "geoPoint": {"lat": 26.10037, "lon": -80.39977}}, {"facility": "Orita Clinical Research", "status": null, "city": "Decatur", "state": "Georgia", "zip": "30034", "country": "United States", "geoPoint": {"lat": 33.77483, "lon": -84.29631}}, {"facility": "Bingham Memorial Hospital", "status": null, "city": "Blackfoot", "state": "Idaho", "zip": "83221", "country": "United States", "geoPoint": {"lat": 43.19047, "lon": -112.34498}}, {"facility": "St. Luke's Humphreys Diabetes Center: Boise", "status": null, "city": "Boise", "state": "Idaho", "zip": "83702", "country": "United States", "geoPoint": {"lat": 43.6135, "lon": -116.20345}}, {"facility": "Cotton O'Neil Diabetes & Endocrinology", "status": null, "city": "Topeka", "state": "Kansas", "zip": "66606", "country": "United States", "geoPoint": {"lat": 39.04833, "lon": -95.67804}}, {"facility": "The Research Group of Lexington", "status": null, "city": "Lexington", "state": "Kentucky", "zip": "40503", "country": "United States", "geoPoint": {"lat": 37.98869, "lon": -84.47772}}, {"facility": "Clinvest Headlands Llc", "status": null, "city": "Springfield", "state": "Missouri", "zip": "65807", "country": "United States", "geoPoint": {"lat": 37.21533, "lon": -93.29824}}, {"facility": "Richmond University Medical Center", "status": null, "city": "Staten Island", "state": "New York", "zip": "10310", "country": "United States", "geoPoint": {"lat": 40.56233, "lon": -74.13986}}, {"facility": "Velocity Clinical Research, Mt. Auburn", "status": null, "city": "Cincinnati", "state": "Ohio", "zip": "45219", "country": "United States", "geoPoint": {"lat": 39.12711, "lon": -84.51439}}, {"facility": "Velocity Clinical Research, Medford", "status": null, "city": "Medford", "state": "Oregon", "zip": "97504", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Tristar Clinical Investigations", "status": null, "city": "Philadelphia", "state": "Pennsylvania", "zip": "19114", "country": "United States", "geoPoint": {"lat": 39.95238, "lon": -75.16362}}, {"facility": "Frontier Clinical Research, LLC", "status": null, "city": "Scottdale", "state": "Pennsylvania", "zip": "15683", "country": "United States", "geoPoint": {"lat": 40.10035, "lon": -79.58698}}, {"facility": "Lifedoc Research - Lenox Park Drive", "status": null, "city": "Memphis", "state": "Tennessee", "zip": "38115", "country": "United States", "geoPoint": {"lat": 35.14953, "lon": -90.04898}}, {"facility": "Consano Clinical Research, LLC", "status": null, "city": "Shavano Park", "state": "Texas", "zip": "78231", "country": "United States", "geoPoint": {"lat": 29.58495, "lon": -98.55252}}, {"facility": "Texas Valley Clinical Research", "status": null, "city": "Weslaco", "state": "Texas", "zip": "78596", "country": "United States", "geoPoint": {"lat": 26.15952, "lon": -97.99084}}, {"facility": "CEDOES", "status": null, "city": "Vitória", "state": "Espírito Santo", "zip": "29055450", "country": "Brazil", "geoPoint": {"lat": -20.31944, "lon": -40.33778}}, {"facility": "L2IP - Instituto de Pesquisas Clínicas", "status": null, "city": "Brasília", "state": "Federal District", "zip": "70200730", "country": "Brazil", "geoPoint": {"lat": -15.77972, "lon": -47.92972}}, {"facility": "Quanta Diagnóstico e Terapia", "status": null, "city": "Curitiba", "state": "Paraná", "zip": "80040-110", "country": "Brazil", "geoPoint": {"lat": -25.42778, "lon": -49.27306}}, {"facility": "Insight Centro de Pesquisas", "status": null, "city": "Porto Alegre", "state": "Rio Grande do Sul", "zip": "90560-003", "country": "Brazil", "geoPoint": {"lat": -30.03283, "lon": -51.23019}}, {"facility": "Centro de Pesquisa Sao Lucas", "status": null, "city": "Campinas", "state": "São Paulo", "zip": "13060-803", "country": "Brazil", "geoPoint": {"lat": -22.90556, "lon": -47.06083}}, {"facility": "Centro Multidisciplinar de Estudos Clinicos", "status": null, "city": "São Bernardo do Campo", "state": "São Paulo", "zip": "09715-090", "country": "Brazil", "geoPoint": {"lat": -23.69389, "lon": -46.565}}, {"facility": "ISPEM - Instituto São José dos Campos em Pesquisas Médicas", "status": null, "city": "São José dos Campos", "state": "São Paulo", "zip": "12243-280", "country": "Brazil", "geoPoint": {"lat": -23.17944, "lon": -45.88694}}, {"facility": "IBPClin - Instituto Brasil de Pesquisa Clínica", "status": null, "city": "Rio de Janeiro", "state": null, "zip": "20241-180", "country": "Brazil", "geoPoint": {"lat": -22.90642, "lon": -43.18223}}, {"facility": "CPQuali Pesquisa Clínica", "status": null, "city": "São Paulo", "state": null, "zip": "01228-000", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "The Second People's Hospital of Hefei", "status": null, "city": "Hefei", "state": "Anhui", "zip": "230011", "country": "China", "geoPoint": {"lat": 31.86389, "lon": 117.28083}}, {"facility": "Wannan Medical College Yijishan Hospital", "status": null, "city": "Wuhu", "state": "Anhui", "zip": "241001", "country": "China", "geoPoint": {"lat": 31.35259, "lon": 118.42947}}, {"facility": "Beijing Hospital", "status": null, "city": "Beijing", "state": "Beijing Municipality", "zip": "100051", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "Chongqing General Hospital", "status": null, "city": "Chongqing", "state": "Chongqing Municipality", "zip": "401147", "country": "China", "geoPoint": {"lat": 29.56026, "lon": 106.55771}}, {"facility": "The First Affiliated Hospital of Henan University of Science &Technology", "status": null, "city": "Luoyang Shi", "state": "Henan", "zip": "471003", "country": "China", "geoPoint": null}, {"facility": "The Second Affiliated Hospital of Zhengzhou University", "status": null, "city": "Zhengzhou", "state": "Henan", "zip": "450014", "country": "China", "geoPoint": {"lat": 34.75778, "lon": 113.64861}}, {"facility": "The Second Affiliated Hospital of Nanjing Medical University", "status": null, "city": "Nanjing", "state": "Jiangsu", "zip": "210011", "country": "China", "geoPoint": {"lat": 32.06167, "lon": 118.77778}}, {"facility": "Nanjing First Hospital", "status": null, "city": "Nanjing", "state": "Jiangsu", "zip": "210012", "country": "China", "geoPoint": {"lat": 32.06167, "lon": 118.77778}}, {"facility": "Affiliated Hospital of Jiangsu University", "status": null, "city": "Zhenjiang", "state": "Jiangsu", "zip": "212000", "country": "China", "geoPoint": {"lat": 32.21086, "lon": 119.45508}}, {"facility": "Jinan Central Hospital", "status": null, "city": "Jinan", "state": "Shandong", "zip": "250013", "country": "China", "geoPoint": {"lat": 36.66833, "lon": 116.99722}}, {"facility": "Tokuyama Clinic", "status": null, "city": "Mihama-ku,Chiba City", "state": "Chiba", "zip": "261-0004", "country": "Japan", "geoPoint": {"lat": 35.6, "lon": 140.11667}}, {"facility": "Hasegawa Medical Clinic", "status": null, "city": "Chitose", "state": "Hokkaido", "zip": "066-0032", "country": "Japan", "geoPoint": {"lat": 42.81944, "lon": 141.65222}}, {"facility": "MinamiAkatsukaClinic", "status": null, "city": "Mito", "state": "Ibaraki", "zip": "311-4153", "country": "Japan", "geoPoint": {"lat": 36.35, "lon": 140.45}}, {"facility": "Matoba Internal Medicine Clinic", "status": null, "city": "Ebina", "state": "Kanagawa", "zip": "243-0432", "country": "Japan", "geoPoint": {"lat": 35.38121, "lon": 139.39651}}, {"facility": "Takai Internal Medicine Clinic", "status": null, "city": "Kamakura-shi", "state": "Kanagawa", "zip": "247-0056", "country": "Japan", "geoPoint": null}, {"facility": "Shiraiwa Medical Clinic", "status": null, "city": "Kashihara", "state": "Osaka", "zip": "582-0005", "country": "Japan", "geoPoint": {"lat": 34.58333, "lon": 135.61667}}, {"facility": "The Institute of Medical Science, Asahi Life Foundation", "status": null, "city": "Chuo-ku", "state": "Tokyo", "zip": "103-0002", "country": "Japan", "geoPoint": null}, {"facility": "Tokyo-Eki Center-building Clinic", "status": null, "city": "Chuo-ku", "state": "Tokyo", "zip": "103-0027", "country": "Japan", "geoPoint": null}, {"facility": "Fukuwa Clinic", "status": null, "city": "Chuo-ku", "state": "Tokyo", "zip": "104-0031", "country": "Japan", "geoPoint": null}, {"facility": "Medical Corporation Sato Medical clinic", "status": null, "city": "Ootaku", "state": "Tokyo", "zip": "143-0015", "country": "Japan", "geoPoint": null}, {"facility": "Tama Center Clinic Mirai", "status": null, "city": "Tama", "state": "Tokyo", "zip": "206-0633", "country": "Japan", "geoPoint": {"lat": 35.6436, "lon": 139.46844}}, {"facility": "Jinnouchi Hospital", "status": null, "city": "Kumamoto", "state": null, "zip": "862-0976", "country": "Japan", "geoPoint": {"lat": 32.80589, "lon": 130.69181}}, {"facility": "Kansai Electric Power Hospital", "status": null, "city": "Osaka", "state": null, "zip": "553-0003", "country": "Japan", "geoPoint": {"lat": 34.69379, "lon": 135.50107}}, {"facility": "Abe Clinic", "status": null, "city": "Ōita", "state": null, "zip": "870-0039", "country": "Japan", "geoPoint": {"lat": 33.23333, "lon": 131.6}}, {"facility": "Centro de Endocrinologia y Nutricion", "status": null, "city": "Caguas", "state": null, "zip": "00725", "country": "Puerto Rico", "geoPoint": {"lat": 18.23412, "lon": -66.0485}}, {"facility": "FDI Clinical Research", "status": null, "city": "San Juan", "state": null, "zip": "00927", "country": "Puerto Rico", "geoPoint": {"lat": 18.46633, "lon": -66.10572}}, {"facility": "Diabdana", "status": null, "city": "Oradea", "state": "Bihor County", "zip": "410147", "country": "Romania", "geoPoint": {"lat": 47.0458, "lon": 21.91833}}, {"facility": "C.M.D.T.A. Neomed", "status": null, "city": "Brasov", "state": "Brașov County", "zip": "500283", "country": "Romania", "geoPoint": {"lat": 45.64861, "lon": 25.60613}}, {"facility": "Geea Medical Easy Diet", "status": null, "city": "Bucharest", "state": "Bucharest", "zip": "010627", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Centrul Medical NutriLife", "status": null, "city": "Bucharest", "state": "Bucharest", "zip": "013764", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Centrul Medical Endocrinologie si Diabet Dr. Paveliu", "status": null, "city": "Bucharest", "state": "Bucharest", "zip": "50538", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "CMI DNBM Dr. Pop Lavinia", "status": null, "city": "Baia Mare", "state": "Maramureş", "zip": "430222", "country": "Romania", "geoPoint": {"lat": 47.65729, "lon": 23.56808}}, {"facility": "SC Dentosim Queen SRL - Centrul Medical Diamed", "status": null, "city": "Târgu Mureş", "state": "Mureș County", "zip": "540098", "country": "Romania", "geoPoint": {"lat": 46.54245, "lon": 24.55747}}, {"facility": "Milena Sante", "status": null, "city": "Galați", "state": null, "zip": "800001", "country": "Romania", "geoPoint": {"lat": 45.52281, "lon": 23.06836}}, {"facility": "Diamed Obesity", "status": null, "city": "Galați", "state": null, "zip": "800291", "country": "Romania", "geoPoint": {"lat": 45.52281, "lon": 23.06836}}, {"facility": "Clinica Korall", "status": null, "city": "Satu Mare", "state": null, "zip": "440055", "country": "Romania", "geoPoint": {"lat": 47.79926, "lon": 22.86255}}]
primaryOutcomes	array	[{"measure": "Change From Baseline in Hemoglobin A1c (HbA1c)", "description": "Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A, measured to reflect average plasma glucose concentration over prolonged periods of time.\n\nValues represented under \"Least Squares (LS) Mean\" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤ \\[less than or equal to\\] 8.0%, \\> \\[greater than\\] 8.0%) and SGLT-2 inhibitor use at randomization \\[Yes or No\\]. Variance-covariance structure for change from baseline was unstructured.", "timeFrame": "Baseline, Week 40"}]
secondaryOutcomes	array	[{"measure": "Percentage of Participants With an HbA1c Target Value of < 7.0% (53 mmol/Mol)", "description": "Percentage of participants with an HbA1c target value of less than (\\<) 7.0% (53 millimoles per mole \\[mmol/mol\\]) was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \\>8.0%) and SGLT-2 inhibitor use at randomization \\[Yes or No\\].", "timeFrame": "Week 40"}, {"measure": "Percentage of Participants With an HbA1c Target Value of < 6.5% (48 mmol/Mol)", "description": "Percentage of Participants with an HbA1c target value of less than or equal to (≤) 6.5% (48 mmol/mol) was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \\>8.0%) and SGLT-2 inhibitor use at randomization \\[Yes or No\\].", "timeFrame": "Week 40"}, {"measure": "Change From Baseline in Fasting Serum Glucose (FSG)", "description": "Values represented under \"Least Squares (LS) Mean\" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤ \\[less than or equal to\\] 8.0%, \\> \\[greater than\\] 8.0%) and SGLT-2 inhibitor use at randomization \\[Yes or No\\]. Variance-covariance structure for change from baseline was unstructured.", "timeFrame": "Baseline, Week 40"}, {"measure": "Percent Change From Baseline in Body Weight", "description": "Values represented under \"LS Mean\" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a MMRM with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤8.0%, \\>8.0%) and SGLT-2 inhibitor use at randomization \\[Yes or No\\]. Variance-covariance structure for change from baseline was unstructured.", "timeFrame": "Baseline, Week 40"}, {"measure": "Change From Baseline in Body Weight (kg)", "description": "Values represented under \"LS Mean\" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a MMRM with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤8.0%, \\>8.0%) and SGLT-2 inhibitor use at randomization \\[Yes or No\\]. Variance-covariance structure for change from baseline was unstructured.", "timeFrame": "Baseline, Week 40"}, {"measure": "Percent Change From Baseline in Non-HDL (Non-high-density Lipoprotein) Cholesterol", "description": "Values represented under \"LS Mean\" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \\>8.0%) and SGLT-2 inhibitor use at randomization \\[Yes or No\\]. Variance-covariance structure for change from baseline was unstructured.", "timeFrame": "Baseline, Week 40"}, {"measure": "Percent Change From Baseline in Triglycerides", "description": "Values represented under \"LS Mean\" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \\>8.0%) and SGLT-2 inhibitor use at randomization \\[Yes or No\\]. Variance-covariance structure for change from baseline was unstructured.", "timeFrame": "Baseline, Week 40"}, {"measure": "Change From Baseline in Systolic Blood Pressure (mmHg)", "description": "Values represented under \"LS Mean\" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a MMRM with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤8.0%, \\>8.0%) and SGLT-2 inhibitor use at randomization \\[Yes or No\\]. Variance-covariance structure for change from baseline was unstructured.", "timeFrame": "Baseline, Week 40"}, {"measure": "Change From Baseline in Daily Insulin Glargine Dose (IU/Day)", "description": "Values represented under \"LS Mean\" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \\>8.0%) and SGLT-2 inhibitor use at randomization \\[Yes or No\\]. Variance-covariance structure for change from baseline was unstructured.", "timeFrame": "Baseline, Week 40"}, {"measure": "Percentage of Participants With Greater Than or Equal to (≥) 5% Body Weight Reduction", "description": "Percentage of participants with ≥5% body weight reduction was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \\>8.0%) and SGLT-2 inhibitor use at randomization \\[Yes or No\\].", "timeFrame": "Week 40"}, {"measure": "Percentage of Participants With Greater Than or Equal to (≥) 10% Body Weight Reduction", "description": "Percentage of participants with ≥10% body weight reduction was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \\>8.0%) and SGLT-2 inhibitor use at randomization \\[Yes or No\\].", "timeFrame": "Week 40"}, {"measure": "Percentage of Participants With Greater Than or Equal to (≥) 15% Body Weight Reduction", "description": "Percentage of participants with ≥15% body weight reduction was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \\>8.0%) and SGLT-2 inhibitor use at randomization \\[Yes or No\\].", "timeFrame": "Week 40"}, {"measure": "Change From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Acute Form (Physical-Component and Mental-Component) Scores", "description": "The SF-36v2 is a participant-reported measure designed to assess health status using 36 items across 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The physical functioning domain assesses limitations due to health \"now,\" whereas the remaining domains assess functioning \"in the past week.\" Each domain is scored individually, and information from these 8 domains is aggregated into 2 health component summary scores, the Physical Component Summary and Mental Component Summary. Items are answered on Likert scales of varying lengths (3-point, 5-point, or 6-point scales). Scoring of each domain and both summary scores are norm based and presented in the form of T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores.", "timeFrame": "Baseline, Week 40"}]
studyUrl	string	"https://clinicaltrials.gov/study/NCT06109311"
retrievedAt	string	"2026-10-05T12:05:36.818640+00:00"
errors	array	[]
startDate	string	"2023-11-10"
startDateType	string	"ACTUAL"
primaryCompletionDate	string	"2025-09-15"
primaryCompletionDateType	string	"ACTUAL"
completionDate	string	"2025-09-15"
completionDateType	string	"ACTUAL"
firstPostDate	string	"2023-10-31"
firstPostDateType	string	"ACTUAL"
lastUpdatePostDate	string	"2026-10-01"
lastUpdatePostDateType	string	"ACTUAL"

Error rows contain rowType, nctId when known, studyUrl when valid, retrievedAt and errors. They do not trigger the custom study event. A SUMMARY key-value record reports counts, duration, budget exhaustion and whether a search was incomplete.

Input example

{
  "condition": "diabetes",
  "maxItems": 10
}

Use the input schema for the remaining filters and defaults.

Output example

This is a selected-field excerpt of the first object in sample_output.json.

{
  "rowType": "study",
  "nctId": "NCT06109311",
  "acronym": "ACHIEVE-5",
  "overallStatus": "COMPLETED",
  "lastKnownStatus": null,
  "studyType": "INTERVENTIONAL",
  "phases": [
    "PHASE3"
  ],
  "conditions": [
    "Type 2 Diabetes"
  ],
  "leadSponsor": "Eli Lilly and Company",
  "leadSponsorClass": "INDUSTRY",
  "collaborators": [],
  "enrollmentCount": 546,
  "enrollmentType": "ACTUAL",
  "hasResults": true
}

Pricing

Proposed custom price: $0.002 per successful study event, or $2.00 for 1,000 successful studies. No custom study charge for errors, duplicates or items excluded by maxItems. This is below the saved result-event prices of the most-used comparable returned in the 2026-10-05 Store search, parseforge/clinicaltrials-scraper: $0.008–$0.012 by subscription tier. See PRICING.md for receipts, synthetic-event settings and possible separate platform costs. The owner configures final pricing in Apify Console before publication.

Limits and reliability

• maxItems defaults to 100, accepts 1–100,000 and caps all dataset rows, including errors. Empty search filters browse the latest updated studies within that cap.
• pageSize defaults to 100, accepts 1–1,000 and is reduced to the remaining cap. Search pages are fetched sequentially using official continuation tokens.
• concurrency defaults to 4 and accepts 1–10 for direct ID requests. Search pagination makes one request at a time.
• Each request has a 30-second timeout. Transport failures, HTTP 429 and HTTP 5xx get bounded retries with backoff and a bounded Retry-After wait. Permanent HTTP errors produce diagnostics rather than repeated requests.
• An exhausted search-page request retains a diagnostic row and marks the run failed/incomplete so partial data is visible. Individual lookup or malformed-record errors do not discard other results.
• Source records may be outdated or incomplete. Location text is a registry search, not a geographic-radius filter. Registry pagination is not a guaranteed immutable snapshot.

FAQ

What limits the output? The maxItems input caps output rows; its schema maximum is 100,000. Source availability and errors may yield fewer rows.

Does it need a proxy, login, or API key? The actor calls the public ClinicalTrials.gov API without an upstream key or proxy input.

How is it priced? The study-event proposal in PRICING.md applies to successfully saved study rows. Check the published Store configuration and platform charges for the active cost.

What happens on rate limits? The client retries throttling and transient server failures with backoff and Retry-After. Exhausted requests are reported.

How fresh is the data? Rows reflect the registry response at run time. Registry update dates and retrievedAt serve different purposes.

Does it decide patient eligibility? No. It exports registry eligibility text and status for review, without a patient-specific decision.

Use with AI agents / MCP

An AI agent can call a published actor through the Apify MCP server or Apify API, pass the JSON input, then read the run’s default dataset. Check the actor’s published identifier and permissions in your Apify account.

After the owner publishes the actor, expose its published actor ID through the Apify MCP server. An authorized agent can run it with the input above, read the dataset link from the output schema, and compare studies by condition, sponsor, phase or update date. Include a small maxItems and a run budget. Use nctId, studyUrl, retrievedAt, errors and SUMMARY.incomplete when grounding agent answers. The MCP integration itself has not been exercised in this local build.

Local development

The delivered build uses apify and httpx from the existing shared venv; no package was installed into it. Put input at storage/key_value_stores/default/INPUT.json, then run from this actor directory without the Apify CLI:

$env:APIFY_LOCAL_STORAGE_DIR = "$PWD/storage"
& C:/GritWork/earn/.venv/Scripts/python -m src

Use fresh storage for an independent run; retained dataset rows otherwise remain on disk. The proof harness creates fresh probe directories and preserves earlier sample storage.

& C:/GritWork/earn/.venv/Scripts/python -m pytest -q tests/test_config.py tests/test_normalize.py tests/test_client.py tests/test_runtime.py -p no:cacheprovider
& C:/GritWork/earn/.venv/Scripts/python -m pytest -q -m live -p no:cacheprovider
apify validate-schema
& C:/GritWork/earn/.venv/Scripts/python tools/prove.py

The Dockerfile uses apify/actor-python:3.12. Docker execution and Apify cloud billing/publication are separate owner-side checks; Docker is unavailable in the local verification environment. Official API reference: ClinicalTrials.gov REST API.